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Background
Allergen immunotherapy (AIT) is the etiologic treatment
of the allergic respiratory disease and has the ability to
modify their natural course. In this study we investigated
the efficacy and safety of subcutaneous AIT with Derma-
tophagoides pteronyssinus (DP) in local allergic rhinitis
(LAR).
Methods
Thirty-six subjects with LAR to DP were selected to parti-
cipate in a double-blind, placebo-controlled, parallel-
group, phase II clinical trial of subcutaneous AIT in LAR.
The patients were randomized to receive AIT-DP with
Pangramin PLUS, ALK, DP, or placebo for a period of 24
months. The primary endpoint was total symptoms (TSS)
and total medication scores (TMS). Secondary endpoints
were: total combined symptom+medication scores (TCS),
daily symptoms score (DSS), daily medication score
(DMS), medication free days (MFD), skin testing, nasal
allergen provocation test (NAPT-DP), and adverse events.
Serum and nasal lavage samples were obtained for immu-
nological studies.
Results
AIT-DP induced a clinically relevant and significant
improvement compared to placebo with a 47% of reduc-
tion in TSS (0.60 vs 1.14; p<0.001) and a 51.2% in TMS
(0.65 vs 1.34; p=0.002). At 6-12-18-24 months significant
improvements in TCS (p=0.046; p=0.037; p=0.011;
p=0.007) and DSS (p=0.003; p=0.012; p<0.001; p<0.001);
and at 24 months in DMS (p=0.014), and MFD (p=0.031)
compared to placebo were also observed. AIT-DP induced
an increase in nasal tolerance to NPAT-DP at 6-12-18-24
months (p=0.003; p<0.001; p<0.001; p<0.001) compared to
placebo, with negative NAPT-DP in the 50% of patients.
One patient with AIT-DP had a local moderate reaction
solved without systemic treatment, no systemic reactions
occurred.
Conclusion
Subcutaneous allergen immunotherapy with Dermatopha-
goides Pteronyssinus has demonstrated to be an effective
and well-tolerated treatment in LAR. This phase II study
provides the indication for AIT in LAR. To our knowledge
this is the first study carried out in patients with LAR in
patients sensitised to house dust mite.
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